Wegovy
How a blockbuster weight-loss drug made Ireland the fastest-growing economy in the world
Unprecedented surge in Irish exports this year was almost entirely driven by shipments of drug ingredients for Eli Lilly
Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Novo Nordisk appoints Dilek Dogan Gurluk as new head of Irish business
Wegovy maker’s top investor proposes international board overhaul
Weight-loss drugmaker Novo Nordisk to cut 9,000 jobs amid increased competition
The company’s shares have nearly halved since the start of the year and expects slower growth this year
Serena Williams’ endorsement of weight loss medication is a game changer
Williams is not the first sportsperson to promote GLP-1 weight loss medication but she is the most high profile and easily the most significant
The history of weight loss is littered with supposed quick fixes
GLP-1 agonists such as Ozempic and Wegovy have a lot of promise
Black market weight-loss drugs ‘not worth the risk’, warn pharmacists
Union advises people to only purchase drugs from registered pharmacies
‘A slow-moving car crash’: Novo Nordisk’s troubles keep mounting
Novo Nordisk has now lost two-thirds of its value in little over a year
Trump tariff letters unnerve investors with banks worst hit as markets drop
Pharma companies also volatile in wake of letters from US president to 17 of them demanding lower prices
In Ozempic’s home town they fear two things: a new set of tariffs, and a company in Kinsale
Pharmaceutical giants in Europe brace themselves for a tariffs fight that is likely still to come
Hundreds of weight loss and diabetes jab users in UK report pancreas problems
Health officials begin a study into potential side-effects of drugs such as Mounjaro, Wegovy and Ozempic
Maker of Ozempic and Wegovy broke advertising rules, regulator finds
‘Significant number of non-compliances’ by pharmaceutical firm behind weight loss drugs
Ousted Novo Nordisk CEO pays for investors’ inflated hopes
Investor expectations, it seems, are harder to manage than blood sugar
Novo Nordisk cuts sales forecasts on lower US demand for obesity drug
First-quarter sales rise 18 per cent but Danish pharma group blames custom preparations at pharmacies for weaker take-up
Lilly’s weight loss pill is a ‘landmark moment’ in the obesity fight
Prof Donal O’Shea hails breakthrough and says it may play key role in reshaping treatments
Weight loss drug Wegovy to cost around €220 a month as supplies go on market in Ireland
Weight loss drug is not yet approved for reimbursement under Drug Payment Scheme or for medical card patients
Wegovy: The obesity ‘wonderdrug’ comes to Ireland, but it will cost you
Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now at least
Generic drugmaker races to launch versions of blockbuster obesity drugs
Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year
Novo Nordisk to explore how obesity drugs can help patients with addiction
Danish obesity drug giant looking at whether its semaglutide drug can reduce cravings associated with addiction
SlimFast’s rise and fall: Why Glanbia is moving to offload product
Glanbia's once-popular weight-loss product has fallen out of favour with consumers
Monitoring Ozempic use in sport: the miracle drug that surely swerves the doping code?
The World Anti-Doping Agency has added the active ingredient semaglutide to its watch-list for 2025
Insurers will not cover obesity drugs that will cost users €2,500-plus a year
Patients looking to access Eli Lilly’s Mounjaro from next week will have to pay privately
Electricity network upgrades likely to see user bills rise
Seen & heard: Developers summoned; Xerotech on the brink; Glencore eyes Pallas Green sale; CRH invests in 3D; Mounjaro arrives; and O’Hara brewery talks
Lilly’s Zepbound tops Novo Nordisk’s Wegovy for weight loss in head-to-head trial
Companies competing for leadership in fast-growing market where supply continues to be an issue
Sharp increase in number of illegal weight loss drugs seized
HPRA warns of risks of illegal, counterfeit versions of drugs such as Ozempic and Wegovy, saying they pose ‘significant risk’
Obesity drugmaker Novo Nordisk misses profit forecast
Danish company employs about 450 people in Ireland
Novo Nordisk drops Dublin factory plan
Seen & Heard: Inheritance tax reduction, Press Up stake and Spar sale
Large increase in number of fake weight-loss drugs seized by watchdog in 2024
Officials warned consumers of risks from falsified versions of Ozempic and Wegovy
Ozempic and Wegovy maker Novo Nordisk set to build large manufacturing facility in Dublin
News of new factory comes after Danish group announced in December the purchase of drug manufacturing plant in Athlone in order to keep up with demand for weight-loss drugs
Ozempic maker Novo Nordisk buys Irish drug manufacturing plant in €85m deal
Danish weight loss and diabetes specialist is looking to develop a tablet form of its blockbuster obesity treatments
Weight-loss drugs hurt snack company shares
Concerns about weight-loss drugs hurting sales are ‘overblown’ say Citi analysts but investors are worried
The Truth About the ‘Skinny’ Jab: Are weight-loss injections a magic wand or potential health disaster?
Television: Presenter Anna Richardson explores how drugs like Ozempic and Wegovy work and the potential side effects
Obesity drugs make Novo Nordisk Europe’s biggest company
Company boosted by trial results showing weight loss drug also cuts risk of heart attack by 20%
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
The GlossOpens in new window
Read the digital edition of The Gloss magazine now
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices